CN105708832A - Medicine composition for improving docetaxel oral bioavailability - Google Patents

Medicine composition for improving docetaxel oral bioavailability Download PDF

Info

Publication number
CN105708832A
CN105708832A CN201610135877.0A CN201610135877A CN105708832A CN 105708832 A CN105708832 A CN 105708832A CN 201610135877 A CN201610135877 A CN 201610135877A CN 105708832 A CN105708832 A CN 105708832A
Authority
CN
China
Prior art keywords
docetaxel
group
oral
quercetin
ampelopsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610135877.0A
Other languages
Chinese (zh)
Inventor
钱帅
郝天云
高缘
张建军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201610135877.0A priority Critical patent/CN105708832A/en
Publication of CN105708832A publication Critical patent/CN105708832A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a medicine composition for improving docetaxel oral bioavailability and belongs to the technical field of medicine. Flavone compounds comprising quercetin, myricetin and baicalein are combined with docetaxel according to a certain proportion, so that oral bioavailability of docetaxel is improved.

Description

A kind of pharmaceutical composition improving Docetaxel oral administration biaavailability
Technical field
The present invention relates to a kind of pharmaceutical composition improving Docetaxel oral administration biaavailability, belong to technical field of pharmaceuticals.
Background technology
Docetaxel is a kind of compound with notable active anticancer, belongs to mitotic inhibitor, by promoting that micro-pipe is formed, and suppresses the depolymerization of micro-pipe to make microtubule stabilization, and blocks cellular is in G2 and M phase, the mitosis of final anticancer and propagation.Docetaxel all has good result for ovarian cancer, carcinoma of prostate, hepatocarcinoma, advanced breast cancer and gastric cancer etc..
Docetaxel is insoluble in water, and under room temperature, the dissolubility in water is only 0.5 μ g/mL, and the commercial preparation of current Docetaxel is injection, and preparation is contained within the Tween 80 of high concentration.Owing to Tween 80 has hemolytic, serious anaphylaxis, the severe allergy symptom such as including hypotension, angioedema, dyspnea and rubella can be caused after injection, bring painful and serious discomfort to others, directly affect the use of this medicine.Therefore, changing the administering mode of Docetaxel, slowing down or eliminating the injection side effect of Tween 80 is research and develop focus and difficult point.
Owing to Docetaxel is the substrate of outer row's property transporter P-gp and Cytochrome P450 isozyme CYP3A4, its oral absorption is limited by outer row's property transporter P-gp and is difficult to oral absorption, strong liver sausage first pass effect also leads to its relatively low blood drug level simultaneously, so that Docetaxel oral administration biaavailability is low.We find through lot of experiments research, are used with Docetaxel Combined with Oral by Chinese medicine flavone compound, can improve the oral absorption of Docetaxel.Also do not find that Docetaxel and chromocor compound are used in combination to improve the relevant report of the body absorption of Docetaxel at present.
Summary of the invention
The technical scheme is that and provide a kind of pharmaceutical composition improving Docetaxel oral administration biaavailability.
Pharmaceutical composition of the present invention contains chromocor compound and Docetaxel, and chromocor compound therein comprises ampelopsin, Quercetin and baicalin.In compositions, Docetaxel and chromocor compound weight ratio are 40: 2.5-40: 40, and the weight ratio of optimization is 40: 5-40: 20.
Heretofore described compositions adopts oral administration, reduces the toxic and side effects of drug administration by injection, significantly improves the oral absorption of Docetaxel.
Accompanying drawing explanation
Fig. 1: Docetaxel (40mg/kg) group and ampelopsin (2.5mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 2: Docetaxel (40mg/kg) group and ampelopsin (10mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 3: Docetaxel (40mg/kg) group and ampelopsin (40mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 4: Docetaxel (40mg/kg) group and baicalin (2.5mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 5: Docetaxel (40mg/kg) group and baicalin (10mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 6: Docetaxel (40mg/kg) group and baicalin (40mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 7: Docetaxel (40mg/kg) group and Quercetin (2.5mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 8: Docetaxel (40mg/kg) group and Quercetin (10mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Fig. 9: Docetaxel (40mg/kg) group and Quercetin (40mg/kg)+Docetaxel (40mg/kg) organize blood concentration-time curve
Detailed description of the invention
Below by way of detailed description of the invention, the foregoing of the present invention is described in further detail, it is not intended that embodiment limitation of the present invention, and the beneficial effect of of the present invention medicine is expanded on further by tests below.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 1 ampelopsin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and ampelopsin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Ampelopsin+Docetaxel group: ampelopsin (2.5mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 1 is seen according to the short Docetaxel plasma drug level-time graph of the ampelopsin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with ampelopsin+Docetaxel group is as follows:
t1/2: biological half-life: Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible ampelopsin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 1.94 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 2 ampelopsin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and ampelopsin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Ampelopsin+Docetaxel group: ampelopsin (10mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 2 is seen according to the short Docetaxel plasma drug level-time graph of the ampelopsin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with ampelopsin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible ampelopsin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 2.14 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 3 ampelopsin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and ampelopsin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Ampelopsin+Docetaxel group: ampelopsin (40mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 3 is seen according to the short Docetaxel plasma drug level-time graph of the ampelopsin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with ampelopsin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible ampelopsin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 2.17 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 4 baicalin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and baicalin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Baicalin+Docetaxel group: baicalin (2.5mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 4 is seen according to the short Docetaxel plasma drug level-time graph of the baicalin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with baicalin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve: RB%: relative bioavailability.
Visible baicalin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 1.63 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 5 baicalin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and baicalin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Baicalin+Docetaxel group: baicalin (10mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 5 is seen according to the short Docetaxel plasma drug level-time graph of the baicalin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with baicalin+Docetaxel group is as follows:
t1/2: biological half-life: Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible baicalin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 1.77 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 6 baicalin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and baicalin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Baicalin+Docetaxel group: baicalin (40mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 6 is seen according to the short Docetaxel plasma drug level-time graph of the baicalin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with baicalin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible baicalin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 1.67 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 7 Quercetin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and Quercetin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Quercetin+Docetaxel group: Quercetin (2.5mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 7 is seen according to the short Docetaxel plasma drug level-time graph of the Quercetin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with Quercetin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve: RB%: relative bioavailability.
Visible Quercetin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 1.9 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 8 Quercetin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and Quercetin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Quercetin+Docetaxel group: Quercetin (10mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 8 is seen according to the short Docetaxel plasma drug level-time graph of the Quercetin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with Quercetin+Docetaxel group is as follows:
t1/2: biological half-life；Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible Quercetin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 2.04 times.
The pharmacokinetic studies of the short Docetaxel oral absorption of embodiment 9 Quercetin
Experimental program: SD rat, 250-300 gram, male, it is randomly divided into Docetaxel group and Quercetin+Docetaxel group, often group 6, two groups of rat oral gavage administering modes are as follows:
Docetaxel group: Docetaxel (40mg/kg) is individually dosed.
Quercetin+Docetaxel group: Quercetin (40mg/kg) and Docetaxel (40mg/kg) administering drug combinations.
After oral administration, take blood 0.4ml, centrifuging and taking upper plasma respectively at 5min, 15min, 30min, 45min, 60min, 90min, 2h, 3h, 4h, 6h, 8h, detect Docetaxel blood drug level, calculate area and relative bioavailability under its pharmaceutical concentration-time curve.
Experimental result:
Fig. 9 is seen according to the short Docetaxel plasma drug level-time graph of the Quercetin that pharmacokinetic studies result is corresponding.
The Docetaxel group pharmacokinetic parameters corresponding with Quercetin+Docetaxel group is as follows:
t1/2: biological half-life: Tmax: peak time；Cmax: maximum plasma concentration；AUC: area under drug-time curve；RB%: relative bioavailability.
Visible Quercetin and Docetaxel Combined with Oral are remarkably improved the oral absorption of Docetaxel, and the oral relative bioavailability of Docetaxel improves 2.08 times.

Claims (2)

1. the pharmaceutical composition improving Docetaxel oral administration biaavailability, it is by Docetaxel and chromocor compound Combined with Oral, thus increasing the oral administration biaavailability of Docetaxel, described chromocor compound is the one in ampelopsin, Quercetin and baicalin.
2. the pharmaceutical composition improving Docetaxel oral administration biaavailability as described in claims 1, it is characterized in that in compositions, the weight ratio of Docetaxel and chromocor compound is 40: 2.5-40: 40, after optimizing further, in compositions, the weight ratio of Docetaxel and chromocor compound is 40: 5-40: 20.
CN201610135877.0A 2016-03-08 2016-03-08 Medicine composition for improving docetaxel oral bioavailability Pending CN105708832A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610135877.0A CN105708832A (en) 2016-03-08 2016-03-08 Medicine composition for improving docetaxel oral bioavailability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610135877.0A CN105708832A (en) 2016-03-08 2016-03-08 Medicine composition for improving docetaxel oral bioavailability

Publications (1)

Publication Number Publication Date
CN105708832A true CN105708832A (en) 2016-06-29

Family

ID=56158835

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610135877.0A Pending CN105708832A (en) 2016-03-08 2016-03-08 Medicine composition for improving docetaxel oral bioavailability

Country Status (1)

Country Link
CN (1) CN105708832A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309411A (en) * 2016-09-23 2017-01-11 潍坊医学院 Quercetin and paclitaxel co-transportation pulmonary inhaled nanometer targeted porous polymer particle and preparation method thereof
CN107501211A (en) * 2017-07-05 2017-12-22 中国药科大学 The common amorphous substance of Docetaxel flavones

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101836958A (en) * 2009-03-20 2010-09-22 北京大学 Preparation of taxane pH sensitive nanoparticles composite for oral administration and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101836958A (en) * 2009-03-20 2010-09-22 北京大学 Preparation of taxane pH sensitive nanoparticles composite for oral administration and application thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JUN-SHIK CHOI ET AL.: "Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
JUN-SHIK CHOI ET AL.: "Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》 *
PIWEN WANG ET AL.: "Sensitization to docetaxel in prostate cancer cells by green tea and quercetin", 《JOURNAL OF NUTRITIONAL BIOCHEMISTRY》 *
S. C. SHIN ET AL.: "Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein", 《PHARMAZIE》 *
SANG-JOON CHOI ET AL.: "Effects of Myricetin on the Bioavailability of Doxorubicin for Oral Drug Delicery in Rats: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Myricetin", 《ARCH PHARM RES》 *
TIANYUN HAO ET AL.: "Enhanced oral bioavailability of docetaxel in rats combined with myricetin: In situ and in vivo evidences", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》 *
TRIPTA BANSAL ET AL.: "Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy", 《J PHARM PHARMACEUT SCI》 *
曹轶等: "P-糖蛋白抑制剂对紫杉醇大鼠体内药动学的影响", 《中国医院药学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309411A (en) * 2016-09-23 2017-01-11 潍坊医学院 Quercetin and paclitaxel co-transportation pulmonary inhaled nanometer targeted porous polymer particle and preparation method thereof
CN106309411B (en) * 2016-09-23 2019-05-03 潍坊医学院 A kind of Quercetin and taxol convey lung sucking nano target porous polymeric particle and preparation method thereof altogether
CN107501211A (en) * 2017-07-05 2017-12-22 中国药科大学 The common amorphous substance of Docetaxel flavones

Similar Documents

Publication Publication Date Title
NZ708506A (en) Methods of treating bladder cancer
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
CN105708832A (en) Medicine composition for improving docetaxel oral bioavailability
JP2014530181A5 (en)
RU2012108144A (en) ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES
CN102125579B (en) Novel application of 5-bit modified 2'deoxycytidine derivative or phosphate thereof in the preparation of medicaments
Tomono et al. Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient
CN101467967B (en) Double-element solution type preparation for intravenous injection and intracerebral injection
CN103284947A (en) Evodiamine nanoemulsion
CN102961342B (en) Nanoscale capecitabine and preparation method thereof
CN101559037B (en) Binary solution type preparation for intravenous injection and intracerebral injection
CN104146999A (en) Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof
CN103356729B (en) Chinese medicinal composition capable of reducing cancer chemotherapy cid-associated diarrhea, preparing method and application thereof
Cupp et al. A rare case of primary retroperitoneal mucinous adenocarcinoma: A case report
CN102000334B (en) Compound preparation for treating depression
CN102526033B (en) Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation
Greenhill Gemcitabine confirmed as the first-line therapy for pancreatic cancer
CN107157979A (en) Application of the tussilagin ester in cancer therapy drug is prepared
CN102309491A (en) Tegafur and gimeracil compound injecta
CN101229125A (en) Microemulsion injection containing injectio natarii norcantharidatis
MX2017009733A (en) Use of a mixture of modified glucose polymers for reducing tumor metastasis.
CN102552270A (en) Composition prepared by epigallocatechin gallate and 5-fluorouracil for inhibiting tumor cell proliferation
CN103479613A (en) Application of fluoro taxane derivative in preparation of liver cancer treating drugs
CN103263456B (en) Traditional chinese medicine composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160629